First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 HBM9378/WIN378 has the...
COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 HBM9378/WIN378 has the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.